Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the safety, tolerability and preliminary efficacy of
FP-1201 (Interferon Beta) in patients with Acute Lung Injury (ALI) and Acute Respiratory
Distress Syndrome (ARDS).